<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381091</url>
  </required_header>
  <id_info>
    <org_study_id>SNT-EAP-IDE-004</org_study_id>
    <nct_id>NCT04381091</nct_id>
  </id_info>
  <brief_title>Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study</brief_title>
  <acronym>US EAP LHON</acronym>
  <official_title>Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santhera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santhera Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy
      who completed the LEROS Study
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Leber's Hereditary Optic Neuropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone 150 MG Oral Tablet</intervention_name>
    <description>idebenone 900 mg/day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who completed the LEROS study, who attended the end of study visit in LEROS
             and who in the opinion of investigator could benefit from continuation of idebenone
             treatment.

          -  Signed and dated Informed Consent Form (to be obtained at the Enrollment Visit from
             patient or parent/legal guardian (if applicable) prior to dispensing idebenone to the
             patient).

        Exclusion Criteria:

          -  Patients who, in the opinion of the LEROS investigator, had unacceptable tolerability
             of idebenone treatment in LEROS trial.

          -  Patients who prematurely discontinued the LEROS study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Levin, MD, PhD</last_name>
    <phone>+1-650-596-4220</phone>
    <email>levinmh@pamf.org</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

